<i>STK11</i>/<i>TP53</i> co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.
Abdul Rafeh Naqash(Oklahoma City University), Hirva Mamdani(Wayne State University), Luis E. Raez(Florida International University), Asaf Maoz(Dana-Farber Cancer Institute), Jia Zeng(Caris Life Sciences (United States)), W. Michael Korn(Itasca Community College), Stephen V. Liu(Georgetown University), Charalampos S. Floudas(National Cancer Institute), Jorge J. Nieva(University of Southern California), Yasmine Baca(Caris Life Sciences (United States)), Joanne Xiu(Caris Life Sciences (United States)), Naoko Takebe(National Cancer Institute), Gilberto Lopes(University of Miami), Chul Geun Kim(Hanyang University), Julia Judd(Palmetto Hematology Oncology), Hossein Borghaei(Fox Chase Cancer Center)
Cited by 3
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661